JMP Securities Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Sagimet Biosciences (NASDAQ:SGMT) but lowers the price target from $47 to $46.

February 07, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Sagimet Biosciences but lowers the price target from $47 to $46.
While the reduction in price target from $47 to $46 by JMP Securities might seem negative, the maintenance of a Market Outperform rating suggests a continued positive outlook on Sagimet Biosciences. This mixed signal could lead to a neutral short-term impact on SGMT's stock price as investors weigh the slight adjustment in target against the sustained confidence in the company's performance.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90